Pistola, I am certainly no expert. This is my unde

Pistola, I am certainly no expert. This is my understanding at this stage, and obviously all things are subject to change. It is true that CTIX has a number of compounds "in the works." Kevetrin and Prurisol are the lead compounds, an autism compound, which has shown promise is next in development. Leo has told us that they have put that compound on the back-burner . . . CTIX/Kard Scientific does not have the people, resources, time to move forward on all the compounds.

The goal as stated by Leo is to reach a marketing/licensing agreement with Prurisol. Hopefully, Prurisol makes it through trials, goal is a product ready for market in 2015.... could be $500 million or more in annual sales. CTIX does not have the size, sales team, and capacity to market on their own, so a big pharma agreement is the best. The funds from an agreement could then be used to further the Kevetrin trials, which will become more expensive. Leo would like to ideally get Kevetrin through Phase 2 heading into Phase 3 before a buyout. He has told us the value of CTIX goes up exponentially the further along in the process. If results are incredible in Phase 1 or 2, obviously a buyout could happen sooner. Leo is savy, he will maximize shareholder value either way I believe.

Regarding the other compounds... Dr Menon transferred them to Cellceutix several years ago. Likely they will be sold along with the others in a buyout. Perhaps the buyout party will allow Dr Menon to keep some/all the compounds, that is yet to be determined. The autism and other compounds are all many years away from development to a point they would be ready for clinical trials. We CTIX shareholders will not be effected by marketing/licensing agreements . . . at big pharma buyout we could receive cash or shares (valued at the purchase price) in the buyout company. Either way is fine... it's all $$$$ in our pockets! Hope this helps... it is only my understanding and opinion. Others may disagree.